Bavarian Nordic wins EU approval for Imvanex mpox vaccine in children 2-11
Reuters2026/08/07 06:01- Bavarian Nordic won European Commission clearance to extend IMVANEX (MVA-BN) use to children aged 2 to under 12.
- The EU label now covers people aged 2 and older for protection against mpox, smallpox, and vaccinia virus disease.
- Decision follows a Phase 2 study in 227 children showing immune responses non-inferior to adults with a similar safety profile.
- The trial was co-funded by the Coalition for Epidemic Preparedness Innovations.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
